Sorafenib
Sorafenib Brand names, Sorafenib Analogs
Sorafenib Brand Names Mixture
- No information avaliable
Sorafenib Chemical_Formula
C21H16ClF3N4O3
Sorafenib RX_link
No information avaliable
Sorafenib fda sheet
Sorafenib msds (material safety sheet)
Sorafenib Synthesis Reference
No information avaliable
Sorafenib Molecular Weight
464.825 g/mol
Sorafenib Melting Point
No information avaliable
Sorafenib H2O Solubility
Practically insoluble (as tosylate salt)
Sorafenib State
Solid
Sorafenib LogP
3.671
Sorafenib Dosage Forms
Tablets (oral, 200 mg)
Sorafenib Indication
For the treatment of patients with advanced renal cell carcinoma.
Sorafenib Pharmacology
Sorafenib is a multikinase inhibitor targeting several serine/threonine and receptor tyrosine kinases. It is commonly available as a tosylate salt. Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib inhibits tumor growth of the murine renal cell carcinoma, RENCA, and several other human tumor xenografts in athymic mice. A reduction in tumor angiogenesis occurs in some tumor xenograft models.
Sorafenib Absorption
The mean relative bioavailability is 38-49% for the tablet form, when compared to an oral solution. With a high-fat meal, bioavailability is reduced by 29% compared to administration in the fasted state.
Sorafenib side effects and Toxicity
The highest dose of sorafenib studied clinically is 800 mg twice daily. The adverse reactions observed at this dose were primarily diarrhea and dermatologic events. No information is available on symptoms of acute overdose in animals because of the saturation of absorption in oral acute toxicity studies conducted in animals.
Sorafenib Patient Information
Sorafenib Organisms Affected
Humans and other mammals
